Announcements Trials
Browse Landscape

Status

Recruiting 52Completed 35Active not recruiting 31Terminated 11Not yet recruiting 10Suspended 1Enrolling by invitation 1Available 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 51Breast Neoplasms 40Colorectal Neoplasms 26Prostatic Neoplasms 22Lung Neoplasms 18Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 15Stomach Neoplasms 14Brain Neoplasms 11Hematologic Neoplasms 10Pancreatic Neoplasms 9Colonic Neoplasms 9Uterine Cervical Neoplasms 8Urinary Bladder Neoplasms 8Lymphoma, Follicular 8Head and Neck Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Ovarian Neoplasms 7Melanoma 7Liver Neoplasms 7Leukemia, Myeloid, Acute 7Disease 7Anxiety Disorders 7Myasthenia Gravis 6Multiple Myeloma 6Barrett Esophagus 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Rectal Neoplasms 5Lymphoma, Non-Hodgkin 5

Interventions

olverembatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × 1 year × Clear all
NCT07383298 2026-02-03

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

Peking University People's Hospital

Enrolling by invitation
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡